Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced ...

Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of ...

Kardium today announced one-year clinical trial results for its Globe PF pulsed field ablation (PFA) system for treating AFib ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

Field Medical is developing transformative technology for the treatment of all cardiac arrhythmias, including VT and AF. The FieldForce Ablation System, featuring the first built-for-purpose ...